
|Videos|July 19, 2017
PD-L1 Testing in Lung Cancer
Author(s)Aaron S. Mansfield, MD
This video reviews the use of PD-L1 testing in selecting patients for frontline lung cancer treatment with pembrolizumab and examines which patients might not be appropriate for immunotherapy.
Advertisement
In this video, Aaron S. Mansfield, MD, of the Mayo Clinic in Rochester, Minnesota, reviews PD-L1 testing in selecting patients for frontline lung cancer treatment with pembrolizumab, and discusses which patients might not be appropriate for immunotherapy.
Mansfield spoke on this topic last month at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Palbociclib Maintenance Extends PFS in HR+/HER2+ Advanced Breast Cancer
2
FDA Accepts BLA for Ivonescimab Regimen in Pretreated EGFR-Mutated NSCLC
3
New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma
4
FDA Clears IND for Investigational Program in Recurrent High-Grade Glioma
5


































